Related Experiment Video

Updated: Oct 23, 2025

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye
11:49

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

Published on: August 16, 2014

17.1K

Anti-inflammatory activities of a new VEGF blocker, Conbercept

Yang Liu1,2, Hua Fu3, Li Zuo1

  • 1Department of Immunology, Guizhou Medical University, Guiyang, China.

Immunopharmacology and Immunotoxicology
|August 17, 2021
PubMed
Abstract

Insights

Conbercept, a novel vascular endothelial growth factor (VEGF) inhibitor, effectively reduced inflammation in rat models. It significantly decreased paw edema and key inflammatory markers in both acute and chronic arthritis conditions.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Angiogenesis and inflammation are interconnected in numerous human diseases.
  • Vascular Endothelial Growth Factor (VEGF) is a critical proangiogenic factor.
  • Conbercept is a new therapeutic agent designed to inhibit VEGF.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of Conbercept.
  • To evaluate Conbercept's efficacy in models of acute and chronic inflammation.
  • To assess Conbercept's impact on key inflammatory mediators.

Main Methods:

  • A collagen-induced arthritis (CIA) rat model was used to assess chronic anti-inflammatory activity.
  • Enzyme-linked immunosorbent assay (ELISA) measured serum immune factor concentrations.
  • Xylene-induced ear edema in rats evaluated acute anti-inflammatory effects.

Main Results:

  • Conbercept significantly reduced paw edema and arthritis index in CIA rats.
  • Serum levels of VEGF, TNF-α, and IL-6 were decreased by Conbercept treatment.
  • Conbercept demonstrated significant inhibition of xylene-induced ear edema.

Conclusions:

  • Conbercept exhibits potent anti-inflammatory properties.
  • The drug effectively targets both acute and chronic inflammatory processes.
  • Conbercept's mechanism involves the modulation of VEGF and other inflammatory cytokines.
Keywords:
Conberceptangiogenesiscollagen-induced arthritisvascular endothelial growth factorxylene-inducible ear edema

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.2K
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

9.9K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
252
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
291
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
277
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
713